Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery boosts senior management team with appointment of Dr Paul Overton

We have strengthened our senior management team with the appointment of Dr Paul Overton as Senior VP of Business Development, who will focus primarily on expanding Sygnature’s North American market. In this newly created role, he will work alongside Dr Paul Clewlow, Senior VP, Business Development and Executive Board Director.

From left to right: Dr Paul Overton, Dr Simon Hirst, Dr Paul Clewlow

Dr Overton has more than 20 years’ experience in business development roles within the CRO sector. He joins Sygnature from the Global testing specialist Eurofins, where he was Head of European Sales, Marketing and Key Account Management. His previous employers include Evotec and Aptuit where he was Global Head of Business Development and Marketing. Paul has a biological sciences background with a PhD in cell biology obtained from the University of Surrey. After several years working in various research laboratories, he made the move into business development.

Sygnature’s established reputation for quality and scientific excellence in drug discovery was a real attraction to Dr Overton. ‘This is an exciting, dynamic and fast-growing science-driven company. I am really looking forward to building stronger relationships with existing US customers and creating further strategic partnerships with major pharmaceutical and biotech companies,’ he says. ‘A key part of my role will be to build up the US-based business development team in our office in Cambridge, Massachusetts, and expand our footprint in other key areas, including San Diego and San Francisco.’

Dr Clewlow welcomes the fact that Dr Overton is to lead business development activities in North America. ‘More than half of our business is currently in the US, with a mixture of big pharma and VC-backed biotech clients,’ he says. ‘I have known Paul for a number of years and his experience in business development and drug discovery will be invaluable in accelerating our business growth there. He will also make a significant contribution to our global sales and marketing strategy.’

‘There has been a rapid growth in our client base, and we see huge potential for the future with major pharmaceutical and biotech companies,’ says CEO Dr Simon Hirst. ‘Business development is critical to achieving this, and Paul Overton’s experience within larger companies will be extremely helpful to us as we grow. We now over 365 staff at Sygnature and working together Paul and Paul will be key in helping us build on our worldwide client base and forge important strategic partnerships with clients. With the increasing complexity of the integrated drug discovery programmes we undertake, their skills in delivering these projects will be invaluable.’

If you have any questions, would like to find out more about Sygnature Discovery or our drug discovery capabilities then we’d love to hear from you. You can get in touch by using any of the contact forms.

Latest News

View All

Sygnature Discovery wins Medilink Outstanding Achievement Award

Sygnature Discovery expands DMPK capabilities with acquisition…

Sygnature and RenaSci strengthen drug abuse leadership…

Sygnature Discovery boosts senior management team with…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.